


A Novel mechanism for depot-specific leptin gene expression regulation and its persistence after weight loss

Graphical abstract



Authors

Natalie Taege, Jan Hendric Britsemmer, Andreas Israel, ..., Timo Gemoll, Sonja Charlotte Schriever, Henriette Kirchner

Correspondence

henriette.kirchner@uksh.de

In brief

Human metabolism; Epigenetics

Highlights

- *Lep* enhancer DNA methylation and *IncOb* determine fat depot-specific *Lep* regulation
- *Lep* enhancer methylation represses *Lep* in epididymal fat in obese; *IncOb* decreases
- This epigenetic reprogramming is triggered by hypertrophic adipocytes in obesity
- *Lep* enhancer DNA methylation and *IncOb* changes persist after prolonged weight loss



Article

A Novel mechanism for depot-specific leptin gene expression regulation and its persistence after weight loss

Natalie Taege,^{1,2,3} Jan Hendric Britsemmer,^{1,2,3} Andreas Israel,^{3,4} Christin Krause,^{1,2,3} Sina Junge,^{1,2} Annette Feuchtinger,⁶ Siegfried Ussar,^{3,4} Paul Thomas Pfluger,^{3,7,8} Timo Gemoll,⁵ Sonja Charlotte Schriever,^{3,7} and Henriette Kirchner^{1,2,3,9,10,*}

¹Institute for Human Genetics, Division Epigenetics & Metabolism, University of Lübeck, 23562 Lübeck, Germany

²Center of Brain, Behaviour and Metabolism (CBBM), University of Lübeck, 23562 Lübeck, Germany

³German Center for Diabetes Research (DZD), Neuherberg, Germany

⁴Research Group Adipocytes & Metabolism, Institute for Diabetes & Obesity, Helmholtz Diabetes Center, Helmholtz Center Munich, Ingolstädter Landstrasse 1, 85764 Neuherberg, Germany

⁵Department of Surgery, Section for Translational Surgical Oncology and Biobanking, University Hospital Schleswig-Holstein, 23562 Lübeck, Germany

⁶Core Facility Pathology and Tissue Analytics, Helmholtz Munich, Neuherberg, Germany

⁷Research Unit NeuroBiology of Diabetes, Institute for Diabetes and Obesity, Helmholtz Centre Munich, Ingolstädter Landstrasse 1, 85764 Neuherberg, Germany

⁸Division of NeuroBiology of Diabetes, TUM School of Medicine & Health, Technical University of Munich, Munich, Germany

⁹Present address: Ratzeburger Allee 160, 23562 Lübeck, Germany

¹⁰Lead contact

*Correspondence: henriette.kirchner@uksh.de

<https://doi.org/10.1016/j.isci.2026.115101>

SUMMARY

Leptin gene (*Lep*) expression correlates with fat mass but differs between epididymal and inguinal fat depots in obesity. We investigated whether DNA methylation of a *Lep* enhancer (RS1) and the long non-coding RNA *lncOb* epigenetically regulate this depot-specific expression.

We analyzed DNA methylation, *Lep* and *lncOb* expression in fat depots across metabolic states in male C57BL/6 mice using CRISPR-dCas9-KRAB-mediated repression, methylation-sensitive luciferase assays, and mass spectrometry.

Under obesogenic conditions, RS1 methylation increased specifically in hypertrophic adipocytes of epididymal fat, repressing *Lep* transcription. This methylation persisted after long-term weight loss. *lncOb* expression correlated with *Lep* levels but was reduced in epididymal fat during obesity and remained suppressed post-weight loss.

Together, our findings demonstrate that adipocyte *Lep* expression is dynamically regulated by depot-specific epigenetic mechanisms that become dysregulated in obesity and resist reversal by weight loss, providing a unifying molecular mechanism for depot-specific *Lep* expression differences in a state of obesity.

INTRODUCTION

The identification of the adipokine leptin thirty years ago fundamentally advanced our knowledge of the homeostatic regulation of body weight.^{1,2} Leptin primarily targets hypothalamic circuits that trigger an anorexigenic response.² Leptin is expressed and secreted in proportion to fat mass and energy status primarily by the two major white adipose tissue depots: the visceral adipose tissue (VAT, human) or epididymal adipose tissue (eWAT, murine) and the subcutaneous adipose tissue (SAT, human) or inguinal adipose tissue (iWAT, murine).^{3,4} Apart from their location, these two adipose tissue depots differ in their plasticity, progenitor pool, and differentiation capability and eWAT/VAT is associated with metabolic unhealthy tissue expansion in

obesity.^{3–7} Strikingly, previous studies observed a shift in leptin production from VAT/eWAT to SAT/iWAT in obesity.^{8–12} However, the mechanisms driving depot-specific *Lep* expression remain elusive.

Epigenetic regulation, which enables dynamic gene control without altering DNA sequence, could provide an explanation for this depot-specific and fat mass-dependent expression profile. One epigenetic mechanism is DNA methylation. Promoter DNA methylation of *Lep* is associated with inconsistent changes in *Lep* expression depending on the nutritional status of the organism, and cannot solely explain varying *Lep* expression in relation to the nutritional state or fat-depot.^{13–17} Moreover, a distal *Lep* upstream enhancer (RS1) is linked to differential *Lep* expression in the off-spring of high-fat diet (HFD) or triiodothyronine






Figure 1. RS1 DNA methylation and *IncOb* expression differ between eWAT and iWAT in response to diet-induced obesity

(A) Schematic of the DIO model in C57BL/6N mice, with indicated timepoints of fat tissue collection.

(B) Body weight of DIO mice (data published²³).

(C) Plasma leptin levels in weight-, age-, and DIO/control mice housed under the same conditions.

eWAT panels.

(D) *Lep* expression in chow and HFD-fed mice over time, relative to chow week 1.

(E) RS1 DNA methylation at CpG1; additional two CpG sites are shown in Figures S1K and S1L.

(F) Pearson's correlation of RS1 DNA methylation and *Lep* expression analyzed as $-\Delta\text{CT}(\text{Ct}(\text{Lep}) - \text{Ct}(\text{Hprt}))$.

(G) *IncOb* expression in chow and HFD-fed mice, relative to chow week 1.

iWAT panels.

(H) *Lep* expression in chow and HFD-fed mice over time, relative to chow week 1.

(I) RS1 DNA methylation at CpG1; additional two CpG sites are shown in Figures S1M and S1N.

(J) Pearson's correlation of RS1 DNA methylation and *Lep* expression was analyzed as $-\Delta\text{CT}(\text{Ct}(\text{Lep}) - \text{Ct}(\text{Hprt}))$.

(K) *IncOb* expression in chow and HFD-fed mice, relative to chow week 1.

Data are presented as mean \pm standard deviation from the mean (SD). Statistical analysis: two-way ANOVA with Holm-Sidak post hoc test. Significance levels: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$. Note: As we combined two mouse cohorts for the DIO data, the number of mice differs from other timepoints in weeks 4 and 8; individual numbers can be found in the graphs (color-coded). Differences in numbers arise from technical outliers, which are further described in the STAR Methods section. DIO, diet-induced obesity; eWAT, epididymal white adipose tissue; iWAT, inguinal white adipose tissue; HFD, high-fat diet; *Lep*, leptin gene; *IncOb*, long non-coding RNA Ob, and *Hprt*, hypoxanthine guanine phosphoribosyl transferase.

treated dams.^{18,19} Long non-coding RNAs, which regulate gene expression via chromatin interactions or mRNA stabilization, represent another layer of epigenetic control. The long-noncoding RNA *IncOb* is putatively required for high *Lep* expression, the importance of the *IncOb* in eWAT and iWAT upon diet-induced obesity remains unclear.^{20–22} To better understand the epigenetic mechanisms driving fat-depot-specific *Lep* expression during various nutritional states, we analyzed DNA methylation at the distal upstream leptin enhancer (RS1) and *IncOb* expression in eWAT and iWAT during obesity – two mechanisms distinct from promoter methylation.

We identified an eWAT-specific increase in the DNA methylation of the upstream leptin enhancer RS1 during dietary obesity induction in male mice, while DNA methylation in iWAT remained unchanged. The RS1 methylation changes in eWAT originated

from epigenetically reprogrammed large adipocytes, presumably counteracting high *Lep* expression. Moreover, *IncOb* enhanced *Lep* expression in both fat depots but was more dynamic in iWAT.

RESULTS

Changes in the DNA methylation of a *Lep* enhancer and in *IncOb* expression in eWAT and iWAT during diet-induced obesity

The fat-depot-specific regulation of the *Lep* gene expression by epigenetic mechanisms is largely unknown. We first analyzed *Lep* regulation in eWAT and iWAT during the induction and progression of diet-induced obesity (DIO) in mice (Figure 1A). As expected, body weight and plasma leptin levels increased with

Table 1. Human subjects information that underwent bariatric surgery

	Number/mean \pm SD
sex (female/male)	28/12
age [years]	44.6 \pm 12.7
weight [kg]	127.1 \pm 15.2
BMI [kg/m ²]	43.5 \pm 4.3

HFD-feeding (Figures 1B and 1C). In eWAT, *Lep* expression increased initially in week 1 of HFD-feeding but ultimately decreased to chow levels in week 12 (Figure 1D). Together with the initial peak in *Lep* mRNA expression, DNA methylation of the investigated upstream leptin enhancer element RS1 increased initially by 5.2% \pm 3.4% compared to chow (Figure 1E). Subsequently, DNA methylation rose progressively, reaching a 20.6% \pm 2.5% methylation difference in week 12 (Figure 1E). RS1 DNA methylation correlated significantly with *Lep* expression in eWAT, indicating its regulatory effect on *Lep* expression (Figure 1F). Although the long non-coding RNA *IncOb* was described to increase *Lep* expression, it decreased with leptin induction upon HFD-feeding in our study (Figure 1G). Nevertheless, it weakly correlated positively with *Lep* expression ($r = 0.3675$, $p < 0.001$, Figure S1A). In contrast to the observations in eWAT, *Lep* expression in iWAT continuously increased with HFD-feeding (Figure 1H). However, when directly comparing the fold inductions of iWAT to eWAT, *Lep* expression in iWAT did not exceed the *Lep* expression of eWAT (Figure S1B). In line with these observations, leptin protein levels between eWAT and iWAT are similar in week 12 of HFD-feeding (Figure S1C). Despite the significant increase in *Lep* expression, RS1 DNA methylation in iWAT remained unchanged with HFD-feeding (Figure 1I) and no correlation with *Lep* expression was observed (Figure 1J). This indicates a fat-depot-specific regulation of *Lep* expression by *Lep* enhancer RS1 DNA methylation in eWAT. Surprisingly, *IncOb* expression in iWAT was similarly induced in the chow as in the HFD mice and therefore remained unchanged between diet groups (Figure 1K). Opposed to the observations in eWAT, *IncOb* expression correlated strongly with *Lep* expression in iWAT ($r = 0.5367$, $p < 0.001$, Figure S1D) supporting the previously published *Lep*-enhancing role of *IncOb*.^{20,21}

The observed fat-depot specific *Lep* RS1 DNA methylation seems to specifically regulate *Lep* expression in eWAT, since we did not see differences between eWAT and iWAT in HFD-induced changes of glucose and lipid metabolism: After an initial increase in week 1, we observed the downregulation of key glucose and lipid metabolism genes *InsR*, *Glut4*, *ChREBP*, *Srebf1*, *Acc1*, *Fasn*, *Lipe*, *Pnpla2*, and *Ppara* in both eWAT and iWAT after 12 weeks of HFD-feeding (Figures S1E and S1F). This corresponds to the previously published glucose intolerance and elevated insulin plasma levels (Figures S1G and S1H,²³).

Increasing RS1 DNA methylation downregulates gene expression

Since a positive correlation of gene expression with DNA methylation at enhancer sites is generally atypical, and RS1 methylation

in eWAT of mice is high while *Lep* expression decreases to the level of chow with 12 weeks of HFD-feeding (Figures S1I and S1J), we additionally measured RS1 DNA methylation in human VAT samples (Table 1). We observed a negative correlation of *LEP* expression and RS1 DNA methylation in VAT of human subjects with obesity (mean BMI = 43.50 \pm 4.3, $r = -0.3141$, $p = 0.0484$, Figure S3A), thus confirming our results from murine obesity. To investigate the role of RS1 methylation on gene expression mechanistically, we then performed a transcriptional regulation assay by transfecting differentiated 3T3 adipocytes with a catalytically inactive dCas9 fused to a Krüppel-associated box (KRAB) transcriptional repression domain (dCRISPR-KRAB) directed to the RS1 site (Figure 2A). The KRAB-domain significantly downregulated the *Lep* expression confirming that RS1 plays a regulatory role in *Lep* expression (Figure 2B). Furthermore, we analyzed RS1 DNA methylation in 3T3-L1 cells, where *Lep* expression was induced and continued to increase over the time course of differentiation into adipocytes (Figure S3B). Interestingly, RS1 DNA methylation decreased with increasing *Lep* expression, indicating an inhibitory role of RS1 DNA methylation on *Lep* expression (Figure S3C). To confirm that the DNA methylation modulates *Lep* expression, we next performed a methylation-specific luciferase assay, for which the CpG-sites covering RS1 were cloned into a CpG-free firefly luciferase vector that was methylated or mock-methylated before transfection (Figure 2C). DNA methylation at RS1 reduced luciferase expression compared to the mock-methylated control (Figure 2D), indicating either the recruitment of methyl-binding repressor proteins or the inhibition of transcription-stimulating factors. To identify these putative proteins and scrutinize their DNA methylation sensitivity, we performed methylation-specific immunoprecipitations. Methylated and unmethylated oligonucleotide sequences containing the RS1 motif were incubated with proteins isolated from murine eWAT or 3T3 adipocytes. Subsequently, proteins bound to the methylated and unmethylated RS1 motif were identified by mass spectrometry analysis (Figures 2E and 2F). Confirming our hypothesis, in methylated RS1, binding of the transcriptional repressors methyl-CpG binding protein 2 (MECP2, $p = 0.002$ and $\log_2\text{FoldChange} = 1.61$, Figure 2E and Data S1) and methyl-CpG binding domain protein 2 (MBD2, $p = 0.001$, $\log_2\text{FoldChange} = 3.43$, Figure 2F and Data S2) was increased compared to unmethylated RS1. Furthermore, the MAF BZIP transcription factors G (MAFG) and K (MAFK) were enriched in the methylated state (Figures 2E and 2F). Together, these results indicate that the DNA methylation of RS1 leads to transcriptional repression and explain the observed reduction of *Lep* expression in eWAT in week 12 of HFD-feeding.

RS1 DNA methylation is reprogrammed in hypertrophic adipocytes in eWAT of obese mice

Next, we wanted to dissect if the observed increase in *Lep* enhancer DNA methylation in obesity is mediated by central leptin-feedback signaling and quantified *Lep* expression and RS1 DNA methylation in eWAT from leptin-deficient ob/ob mice. These mice produce high amounts of *Lep* mRNA (Figure S4A) but no functional leptin protein due to a mutation introducing a stop codon.¹ RS1 DNA methylation (Figure S4B) was increased




Figure 2. RS1 DNA methylation downregulates *Lep* gene expression

(A) Schematic representation of the CRISPR-KRAB assay set-up.

(B) *Lep* expression after transfection with the CRISPR-KRAB system.

(C) Experimental scheme of luciferase assay, showing CpG-free firefly luciferase vector with RS1 insert.

(D) Relative luciferase activity of methylated versus mock-methylated RS1-firefly constructs. Data were analyzed by two-tailed Student's *t* test. Significance: **p* < 0.05 and ***p* < 0.01.

(E) Volcano plot of proteins differentially abundant from eWAT of DIO mice binding unmethylated vs. methylated RS1 oligonucleotide identified by mass spectrometry.

(F) Volcano plot of proteins differentially abundant from 13-day differentiated 3T3L-1 adipocytes binding to unmethylated vs. methylated RS1 oligonucleotide identified by mass spectrometry. Data are presented as mean \pm SD. DIO, diet-induced obesity; eWAT, epididymal white adipose tissue; *Lep*, leptin gene; KRAB, Krüppel-associated box; 3T3L-1, mouse embryonic fibroblast cell line.

in eWAT of ob/ob mice to a similar extent as observed in the DIO mice compared to chow controls allowing the conclusion that the induction of RS1 DNA methylation with increasing fat mass does not require leptin-feedback signaling.

As leptin-feedback signaling was not the trigger of DNA methylation change, we investigated intra-adipocyte signals since the expansion of adipocyte size due to fat accumulation (hypertrophy) could function as an intracellular driver of the methylation of *Lep* enhancer sites. In eWAT of lean and DIO mice, we found a strong positive correlation of DNA methylation with mean adipocyte size ($r = 0.9474$, $p < 0.001$, Figure 3A), while *Lep* expression and mean adipocyte size did not correlate ($r = 0.4433$, $p = 0.1124$, Figure 3B). Therefore, we next sorted adipocytes from eWAT of chow and DIO mice into large (hypertrophic) and small adipocytes using the COPAS system (Figure 3C). DIO mice displayed a significantly higher body-weight ($\Delta = 5.3 \text{ g} \pm 0.7 \text{ g}$, $p < 0.001$, Figure 3D) compared to chow mice, and RS1 DNA methylation in isolated adipocytes of HFD-fed mice was overall increased by $17.4\% \pm 9.9\%$ (Figure 3E). In line with this RS1 DNA methylation increase, immunohistological stainings of leptin in eWAT sections showed

less leptin protein in DIO mice compared to control mice (Figures 3F and 3G). When stratified by size, we observed similar RS1 DNA methylation in small adipocytes from chow-fed compared to HFD-fed mice (Figure 3H). However, RS1 DNA methylation in large adipocytes from HFD-fed mice was significantly higher compared to chow (Figure 3I), indicating epigenetic reprogramming of the *Lep*-regulating element in hypertrophic adipocytes. Together with the higher RS1 DNA methylation in large adipocytes, leptin protein content was decreased by an average of $30.2 \mu\text{m}^2$ per cell compared to the lean control, confirming the inhibitory effect of the RS1 DNA methylation on leptin expression in hypertrophic adipocytes (Figures 3H and 3I). The difference of leptin protein content per cell in small adipocytes was only on average $19.6 \mu\text{m}^2$. The higher RS1 DNA methylation is in line with our initial finding of increased RS1 DNA methylation in bulk eWAT of DIO mice (Figure 1E), as eWAT of HFD mice contains more large adipocytes than eWAT of chow mice.

RS1 DNA methylation is not reversible with weight loss

Since the DNA methylation of RS1 was induced upon adipocyte hypertrophy, we tested its reversibility by weight loss using a 24-week weight cycling intervention (Figure 4A,²⁴). We introduced a Yoyo group, which was switched from HFD to chow (HC) and was allowed to regain weight by a final HFD-feeding (Figures 4A and 4B). After 12 weeks of weight loss, body weight together with serum leptin and eWAT *Lep* expression levels in HC mice were comparable to the levels of chow controls




Figure 3. Hypertrophic adipocytes trigger changes in RS1 DNA methylation in obesity

(A) Pearson's correlation of RS1 DNA methylation with mean adipocyte size in eWAT of 43 weeks HFD and chow-fed mice.
 (B) Pearson's correlation of *Lep* expression analyzed as $-\Delta\text{CT}(\text{Lep-Hprt})$ with mean adipocyte size in eWAT of 43 weeks HFD- and chow-fed mice.
 (C) Experimental workflow for adipocyte size sorting in eWAT.
 (D) Body weight of mice at sacrifice.
 (E) RS1 DNA methylation in isolated adipocytes from eWAT, additional RS1 CpG sites are shown in Figure S4A.
 (F) Mean area of leptin protein per cell analyzed from immunostainings of eWAT from 42 weeks HFD-fed and chow-fed mice.
 (G) Representative immunostainings of eWAT from mice fed a chow or HFD diet. Left side: scale bars, 100 μm ; right side: scale bars, 50 μm ; 20 \times magnification.
 (H) RS1 DNA methylation in size-sorted adipocytes from eWAT. Additional CpG sites are shown in Figures S5B and S5C.
 (I) Mean area of leptin protein stratified by adipocyte size per cell analyzed from immunostainings of eWAT from 42 weeks HFD-fed, and chow-fed mice.
 Data are presented as mean \pm SD (D–F, H, and I). Statistical analysis: (D and E) Two-tailed Student's *t* test; (F) two-way repeated measures ANOVA with post hoc uncorrected Fisher's LSD test. Significance: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$. eWAT, epididymal white adipose tissue; *Lep*, leptin gene. Black circles indicate chow-fed mice; blue squares indicate HFD-fed mice.




Figure 4. Epigenetic regulation of *Lep* expression is disrupted in hypertrophic adipocytes

(A) Experimental design of the long-term weight cycling study.

(B) Body weight over the course of the study.

(C) Plasma leptin levels (data published²⁴).

eWAT panels.

(D) *Lep* mRNA expression.

(E) RS1 DNA methylation at CpG1; additional CpG sites are shown in Figure S5D.

(F) *IncOb* expression.

iWAT panels.

(G) *Lep* mRNA expression.

(H) RS1 DNA methylation at CpG1, and additional CpG sites are shown in Figure S5E.

(I) *IncOb* expression.

Data are presented as mean \pm SD. (C–I) were analyzed by one-way ANOVA with Holm-Sidak post hoc test, except (H): Kruskal-Wallis test with Dunn's multiple comparison test. Significance: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$. Abbreviations: eWAT, epididymal white adipose tissue; iWAT, inguinal white adipose tissue; *Lep*, leptin gene; *IncOb*, long non-coding RNA Ob.




Figure 5. Overnight fasting is sufficient to change eWAT RS1 DNA methylation in lean-ness but is impaired in obesity

(A) Body weight difference (day of sacrifice – 1 day before sacrifice, within each mouse) in mice fed chow or high-fat diet (HFD) and subsequently fasted overnight (16 h) or left fed *ad libitum* prior to sacrifice.

(B) Plasma leptin levels of fed and 16h fasted mice.

(C) *Lep* mRNA expression in eWAT before and after 16 h of fasting.

(D) RS1 DNA methylation at CpG1 in eWAT before and after 16 h of fasting; other measured CpG sites shown in Figure S3F.

(E) *IncOb* expression in eWAT before and after 16 h of fasting.

Data are presented as mean \pm SD. Data were analyzed using two-way ANOVA with Holm-Sidak post hoc test. Significance: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$. Abbreviations: eWAT, epididymal white adipose tissue; HFD, high-fat diet; *Lep*, leptin gene; *IncOb*, long non-coding RNA Ob.

(Figures 4B–4D). Correspondingly, RS1 DNA methylation in eWAT significantly decreased by weight loss in HC compared to HFD mice (Figure 4E) but still remained increased compared to chow mice. *LncOb* expression did not reverse to lean levels upon weight loss (Figure 4F). Together with the not fully reversed DNA methylation, this indicates a memory of the obese epigenetic signature even after prolonged weight loss intervention.

The reduction of serum leptin levels and *Lep* expression was reversed by weight regain in the Yoyo group, accompanied by increased RS1 DNA methylation returning to the level of the HFD group (Figure 4D). Thus, eWAT expansion in obesity appears to drive *Lep* enhancer DNA methylation.

In iWAT, *Lep* expression was not increased in long-term HFD-fed mice compared to chow controls. Weight loss in HC mice had no significant effect on *Lep* expression in iWAT. However, weight regain in Yoyo mice escalated *Lep* expression in iWAT significantly (Figure 4G). Surprisingly, RS1 DNA methylation increased with HFD-feeding, as observed in eWAT (Figure 4H). This observation could be explained by the longer HFD-feeding of 42 weeks in this study compared to the initial 12-week study, thus indicating that extensive adipose tissue hypertrophy and age may induce sensitivity toward epigenetic reprogramming in iWAT. Upon dietary intervention, RS1 DNA methylation and *IncOb* expression in iWAT returned to the levels of chow-treated mice (HC, Figures 4H and 4I), indicating greater epigenetic plasticity than eWAT.

Similar to the cycling of *Lep* expression in dependence to the feeding regime, we observed a cycling of key glucose and lipid metabolism genes *InsR*, *Glut4*, *ChREBP*, *Srebf1*, *Acc1*, *Fasn*, *Lipe*, *Pnpla2* and *Ppara* in eWAT but not iWAT: With weight reduction after HFD, all genes, but *Fasn*, *Srebf1*, and *Ppara*, were restored in the HC group in eWAT (Figures S6A and S6B). With weight regain, these altered gene expressions decreased

again in the Yoyo group. This cycling in gene expression in eWAT corresponds to the previously published plasma insulin levels (Figure S6C;²⁴).

To finally validate that the epigenetic regulation of *Lep* expression is dysregulated in hypertrophic adipocytes, we analyzed whether RS1 DNA methylation and *IncOb* expression would react to a 16 h overnight fast, which acutely shrinks adipocytes. Overnight fasting significantly reduced body weight in chow and HFD but did not affect plasma leptin levels (Figures 5A and 5B). *Lep* expression decreased upon fasting only in eWAT of chow mice, which was accompanied by an increase in RS1 DNA methylation (Figures 5C and 5D). Overnight fasting in DIO mice did not affect *Lep* expression and DNA methylation in eWAT (Figures 5C and 5D), indicating acute epigenetic inflexibility in obese mice. This is in line with our findings from the long-term weight-loss studies. Furthermore, it supports our finding of an overall higher DNA methylation in small compared to large adipocytes in chow mice (Figure 3H). *LncOb* levels in the metabolically healthy chow mice were downregulated dramatically in fasting, together with the *Lep* expression decrease; however, no changes in the obese mice were observed (Figure 5E). The increase in DNA methylation alongside a reduction in *Lep* expression in chow mice reflects the anticipated relationship between RS1 methylation and *Lep* gene expression, indicating a healthy response to nutritional cues in lean mice. In contrast, fasting did not change RS1 DNA methylation in obese mice, indicating the loss in epigenetic flexibility in obesity (Figure 5D). Similarly, the decrease in *IncOb* upon overnight fasting indicates its relevance for *Lep* expression in eWAT of healthy lean mice, which is lost in obesity.

In summary, we demonstrated that depot-specific epigenetic mechanisms regulate *Lep* gene expression in white adipose tissue. eWAT *Lep* expression surged early during the induction of

DIO and surprisingly decreased again with prolonged HFD exposure. This counter-regulation was likely facilitated by increased RS1 DNA methylation, especially in large hypertrophic eWAT adipocytes, leading to *Lep* deactivation. We believe that this is a compensatory mechanism to counteract massive leptin production in obesity that is only partially reversible with weight loss, contributing to the persistence of obesity-associated epigenetic signatures. Thus, obesity induces a loss of epigenetic flexibility in eWAT, potentially impairing adaptive responses to acute metabolic cues. *LncOb* enhances *Lep* expression in both depots but is more dynamically regulated in iWAT.

DISCUSSION

Lep expression in the adipose tissue involves a complex interplay of regulatory factors,^{20,21,25–27} yet molecular cues determining quantitative expression differences of *Lep* in lean and obese individuals for the two major white adipose tissues remain largely unclear. In this work, we identify a mechanism that provides an explanation for the switch of *Lep* expression from eWAT to iWAT in a state of obesity.^{8–12} We demonstrate that the DNA methylation of the distal leptin enhancer RS1 regulates *Lep* expression specifically in eWAT but not iWAT, which, driven by hypertrophic adipocytes, leads to a reduction in the *Lep* expression of eWAT in manifested diet-induced obesity (equals week 12 DIO). We further show that the RS1 DNA methylation in eWAT is not fully reversible with dietary intervention, indicating a retention of an epigenetic memory.

Lep expression in iWAT was shown to surpass eWAT in late stages of obesity progression,⁸ while *Lep* expression in lean mice was higher in eWAT than iWAT.^{28,29} Concomitantly, *LEP* expression was higher in visceral adipose tissue than in subcutaneous adipose tissue in lean humans, while this inverted in obesity.^{9–12,30} In accordance with these observations, we saw a downregulation of *Lep* expression in the eWAT of obese mice after 12 weeks of HFD-feeding to the levels of lean mice, together with an adipocyte size-dependent change in RS1 DNA methylation. *Lep* expression in iWAT increased constantly without a change in RS1 DNA methylation in our longitudinal HFD cohort. Overall, this indicates that the metabolic status is important for the regulation of *Lep* expression and suggests a regulatory role of RS1 DNA methylation on *Lep* expression specific for eWAT that might contribute to the fat depot-specific *Lep* expression pattern.

DNA methylation plays a vital role in the regulation of gene expression, as DNA methylation of gene promoters is associated with a binary on/off switch of expression, whereas the methylation of enhancer sites regulates transcription more nuanced through protein-DNA binding modulation.^{31,32} Consistent with our findings, a higher DNA methylation of the promoters of *Lep* and *Pparg2* in eWAT, but not iWAT, of DIO mice has already been reported.¹⁴ Surprisingly, RS1 DNA methylation in our study correlated positively with *Lep* expression in eWAT (Figure 1F) and ceased to correlate with the prolonged HFD-feeding of 12 weeks (Figure S1O), indicating a possible downregulatory mechanism of the RS1 DNA methylation in eWAT in progressive stages of obesity. Our thorough mechanistic investigations confirmed the inhibitory effect of RS1 DNA methylation on *Lep*

expression by the enrichment of the transcription repressors MECP2 and MBD binding to this site (Figure 2). This finding is in line with the general observation associating DNA methylation with gene expression downregulation. This counterregulatory epigenetic signature is caused by an epigenetic reprogramming of large adipocytes in eWAT. Large adipocytes displayed higher RS1 DNA methylation than large adipocytes from healthy, lean mice (Figure 3H). The level of RS1 DNA methylation in large adipocytes was similar to that of its small counterparts and ultimately explained the on average 20% higher DNA methylation observed in eWAT of obese compared to lean mice. The previously described uncoupling of eWAT volume from *Lep* expression in obese and aged male mice supports the epigenetic reprogramming observed in large adipocytes.⁸ It is important to note that the leptinemic state remains in HFD-diet fed mice: Leptin protein content remains high in eWAT compared to chow after 12 weeks of HFD, when *Lep* expression is already downregulated. This buffering of leptin protein levels by post-transcriptional changes and/or hormonal cues has been described before.³³ However, leptin protein content per cell is reduced as we demonstrated by immunohistochemistry after 42 weeks of HFD-feeding (Figure 3F). The observation that the *Lep* gene expression of eWAT and iWAT is aligning is supported by similar iWAT and eWAT leptin protein levels after 12 weeks of HFD-feeding. Together with the leptinemic state, diet-induced obese mice remain leptin insensitive.^{34,35} Nevertheless, our data help to further understand the characteristics of white adipose tissue depots and physiologic functions that differ between eWAT and iWAT. These differences are emphasized by the lack of glucose and lipid metabolism gene expression restoration by weight loss in iWAT. However, further studies are needed to understand the physiological relevance and potential clinical applications.

Interestingly, RS1 DNA methylation in eWAT was not restored to levels of lean mice with a prolonged dietary intervention of 12 weeks (Figure 4E). We interpret this as epigenetic inflexibility in metabolic diseases leading to persistent gene expression changes which has previously been described in adipose tissues of humans and mice, where a retention of histone modifications in iWAT and eWAT was demonstrated, leading to persistent transcriptional changes despite considerable weight loss.³⁶ This study together with others suggests an epigenetic regulation of adipose tissue in mice and humans.^{36,37} As we only present limited human data, translation of our findings to humans needs to be further validated: In VAT of obese male and female humans, *LEP* mRNA levels correlate negatively with *LEP* RS1 DNA methylation, consistent with our mouse data (Figure S3a). Of note, extrapolating from murine to human data is complicated by the fact that adipose depots of mice and humans differ in amount and location. Human VAT but not murine eWAT drains directly into the portal vein,³⁸ yet both are associated with metabolically unhealthy tissue expansion.^{3,39} However, in line with our findings that hyperplastic adipocytes in eWAT lead to changes in the RS1 DNA methylation, others showed that eWAT/VAT contains more large adipocytes compared to iWAT/SAT with the latter retaining higher plastic capability.^{39–41} Epigenetic and transcriptional differences between eWAT/VAT and iWAT/SAT were also shown to be translatable into humans regardless of

sex.^{36,37,42} However, future studies should confirm our finding in lean vs. obese iWAT and eWAT biopsies from mice and humans of different sexes.

We further demonstrated that in healthy, lean mice, small adipocytes displayed higher RS1 DNA methylation than large adipocytes that express more leptin. This is substantiated by previous studies of lower *Lep* expression in small compared to large adipocytes,²⁸ alongside reduced *LEP* promoter methylation and increased expression during SAT preadipocyte differentiation.⁴³ Additionally, normal birth weight males showed lower *LEP* promoter DNA methylation after 36 h of fasting, and *Lep* expression and eWAT volume correlated in lean male mice.^{17,29} Strikingly, we demonstrated that already an overnight fasting of 16 h was sufficient to change the RS1 DNA methylation in lean, healthy mice.

While the factors governing *Lep* expression in iWAT remain less understood, several lines of evidence suggest distinct regulatory mechanisms in eWAT. First, eWAT adipocytes exhibit greater hypertrophy than iWAT adipocytes in DIO.^{40,41} We observed that adipocyte size correlated with increased DNA methylation at the *Lep* enhancer RS1, and indeed hypertrophic adipocytes are epigenetically reprogrammed in obesity. Consistent with this, RS1 methylation remained largely unchanged in iWAT during the time frame when eWAT methylation increased. However, prolonged HFD-feeding increased RS1 methylation and decreased *IncOb* expression also in iWAT, suggesting that sustained metabolic stress can impact epigenetics also in iWAT, albeit with greater plasticity, potentially reflecting the overall greater plasticity of iWAT adipocytes.

Furthermore, *IncOb* appears to play a more prominent role in iWAT regulation as seen by the stronger correlation between *IncOb* and *Lep* expression in iWAT, compared to eWAT. Surprisingly, we observed reduced *IncOb* expression in eWAT of DIO mice after only 4 weeks of high-fat diet feeding, a finding that contrasts with reports of elevated *IncOb* in obese mice.²⁰ However, our data align with studies demonstrating higher *IncOb* expression in iWAT but not eWAT of HFD-fed mice and showing that *IncOb* is responsive to nutritional status, decreasing with fasting alongside *Lep* expression.²¹ We confirmed this responsiveness in lean mice. Similar to the RS1 DNA methylation, *IncOb* expression was not reversible to chow levels with prolonged dietary intervention, again confirming the described retention of an epigenetic memory after weight loss.³⁶

In summary, we identified a dynamic fat depot-specific epigenetic regulation of *Lep* expression in eWAT, leading to the switch of leptin production from eWAT to iWAT. Interestingly, the underlying epigenetic reprogramming is triggered by adipocyte hypertrophy and persists after prolonged dietary intervention, indicating a lasting epigenetic memory. Furthermore, we found that *IncOb*, albeit not as the sole determinant, acts as a responsive epigenetic modulator of *Lep* expression, particularly in iWAT.

Limitations of the study

Despite careful discussion, we would like to highlight again the following limitations of our study presented here. All mouse experiments were performed in male mice, whereas the human cohort includes males and females. As we only present limited

human data, the translation of our findings to humans needs to be further validated. Furthermore, sex-specific differences in fat depots are described in the literature; therefore, further investigations are needed to account particularly for these sex-specific differences.

RESOURCE AVAILABILITY

Lead contact

Requests for further information and resources should be directed to and will be fulfilled by the lead contact, Henriette Kirchner (henriette.kirchner@uksh.de).

Materials availability

- All unique/stable reagents generated in this study (i.e., the CpG-free vector containing the RS1 sequence (Luci-RS1-CpGfree) are available from the [lead contact](#) with a completed materials transfer agreement.

Data and code availability

- We included all raw data and mass spectrometry data in the [supplemental information](#).
- This article does not report original code.
- Any additional information required to reanalyze the data reported in this article is available from the [lead contact](#) upon request.

ACKNOWLEDGMENTS

We thank Martina Grohs, Katrin Huber, and Julia Resch for their skillful technical assistance. Furthermore, we thank former lab-member Cathleen Geißler for performing the initial longitudinal mouse studies, and Dr. med. Stefan Wolter, Dr. med. Oliver Mann, and Helen Sievert for collecting and processing the visceral adipose tissue samples. This work was supported in part by the European Research Council ERC-CoG Yoyo-LepReSens (no. 101002247, awarded to PTP), and by research funding from the German Research Foundation DFG (GRK 1957: Adipocyte-Brain Crosstalk; CRC/TR296 LocoTact; KI-1887/2-1; KI-1887/2-2; KI-1887/3).

AUTHOR CONTRIBUTIONS

Natalie Taeye: conceptualization, formal analysis, investigation, methodology, and writing - original draft; **Jan Hendric Britsemmer:** methodology, investigation, and writing - review; **Andreas Israel:** methodology, investigation, and writing - review; **Christin Krause:** methodology and writing - review; **Sina Junge:** investigation and writing - review; **Annette Feuchtinger:** methodology, investigation, and writing - review; **Siegfried Ussar:** resources and writing - review; **Timo Gemoll:** investigation, resources, and writing - review; **Paul Thomas Pfluger:** resources, supervision, funding acquisition, and writing - review; **Sonja Charlotte Schriever:** conceptualization, methodology, investigation, and writing - review and editing; **Henriette Kirchner:** conceptualization, writing - review & editing, supervision, project administration, and funding acquisition.

DECLARATION OF INTERESTS

The authors declare no competing interests.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- [KEY RESOURCES TABLE](#)
- [EXPERIMENTAL MODELS AND STUDY PARTICIPANT DETAILS](#)
 - Diet-induced obesity model
 - Adipocyte size sorting
 - Dietary interventions and genetic alteration

- Human visceral adipose tissue samples
- **METHOD DETAILS**
 - Exclusion criteria for data or subjects
 - Adipocyte size measurement in fixed adipose tissue
 - Immunofluorescent analysis of leptin content
 - Gene expression analysis
 - Methylation analysis
 - Luciferase assay
 - Mass-spectrometry analysis
 - Protein isolation for mass spectrometry
 - 3T3-L1 cell culture differentiation
 - Immunoblotting
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.isci.2026.115101>.

Received: September 4, 2025

Revised: February 7, 2026

Accepted: February 17, 2026

Published: February 25, 2026

REFERENCES

1. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman, J.M. (1994). Positional cloning of the mouse obese gene and its human homologue. *Nature* 372, 425–432. <https://doi.org/10.1038/372425a0>.
2. Friedman, J.M. (2019). Leptin and the endocrine control of energy balance. *Nat. Metab.* 1, 754–764. <https://doi.org/10.1038/s42255-019-0095-y>.
3. Vishvanath, L., and Gupta, R.K. (2019). Contribution of adipogenesis to healthy adipose tissue expansion in obesity. *J. Clin. Investig.* 129, 4022–4031. <https://doi.org/10.1172/JCI129191>.
4. Ibrahim, M.M. (2010). Subcutaneous and visceral adipose tissue: structural and functional differences. *Obes. Rev.* 11, 11–18. <https://doi.org/10.1111/J.1467-789X.2009.00623.X>.
5. Bilal, M., Nawaz, A., Kado, T., Aslam, M.R., Igarashi, Y., Nishimura, A., Watanabe, Y., Kuwano, T., Liu, J., Miwa, H., et al. (2021). Fate of adipocyte progenitors during adipogenesis in mice fed a high-fat diet. *Mol. Metabol.* 54, 101328. <https://doi.org/10.1016/J.MOLMET.2021.101328>.
6. Poret, J.M., Souza-Smith, F., Marcell, S.J., Gaudet, D.A., Tzeng, T.H., Braymer, H.D., Harrison-Bernard, L.M., and Primeaux, S.D. (2018). High fat diet consumption differentially affects adipose tissue inflammation and adipocyte size in obesity-prone and obesity-resistant rats. *Int. J. Obes.* 42, 535–541. <https://doi.org/10.1038/IJO.2017.280>.
7. Sakers, A., De Siqueira, M.K., Seale, P., and Villanueva, C.J. (2022). Adipose-tissue plasticity in health and disease. *Cell* 185, 419–446. <https://doi.org/10.1016/J.CELL.2021.12.016>.
8. Guo, K.Y., Halo, P., Leibel, R.L., and Zhang, Y. (2004). Effects of obesity on the relationship of leptin mRNA expression and adipocyte size in anatomically distinct fat depots in mice. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 287, 112–119. <https://doi.org/10.1152/ajpregu.00028.2004>.
9. Hube, F., Lietz, U., Igel, M., Jensen, P.B., Tornqvist, H., Joost, H.G., and Hauner, H. (1996). Difference in leptin mRNA levels between omental and subcutaneous abdominal adipose tissue from obese humans. *Horm. Metab. Res.* 28, 690–693. <https://doi.org/10.1055/s-2007-979879>.
10. Russell, C.D., Petersen, R.N., Rao, S.P., Ricci, M.R., Prasad, A., Zhang, Y., Brodin, R.E., and Fried, S.K. (1998). Leptin expression in adipose tissue from obese humans: Depot-specific regulation by insulin and dexamethasone. *Am. J. Physiol.* 275, E507–E515. <https://doi.org/10.1152/ajpendo.1998.275.3.E507>.
11. Van Harmelen, V., Reynisdottir, S., Eriksson, P., Thörne, A., Hoffstedt, J., Lönnqvist, F., and Arner, P. (1998). Leptin secretion from subcutaneous and visceral adipose tissue in women. *Diabetes* 47, 913–917. <https://doi.org/10.2337/DIABETES.47.6.913>.
12. Zhang, Y., Zitsman, J.L., Hou, J., Fennoy, I., Guo, K., Feinberg, J., and Leibel, R.L. (2014). Fat cell size and adipokine expression in relation to gender, depot and metabolic risk factors in morbidly obese adolescents. *Obesity* 22, 691–697. <https://doi.org/10.1002/OBY.20528>.
13. Fan, C., Liu, X., Shen, W., Deckelbaum, R.J., and Qi, K. (2011). The Regulation of Leptin, Leptin Receptor and Pro-opiomelanocortin Expression by N-3 PUFAs in Diet-Induced Obese Mice Is Not Related to the Methylation of Their Promoters. *Nutr. Metab.* 8, 31. <https://doi.org/10.1186/1743-7075-8-31>.
14. Zwamborn, R.A.J., Sliker, R.C., Mulder, P.C.A., Zoetemelk, I., Verschuren, L., Suchiman, H.E.D., Toet, K.H., Droog, S., Slagboom, P.E., Kooistra, T., et al. (2017). Prolonged high-fat diet induces gradual and fat depot-specific DNA methylation changes in adult mice. *Sci. Rep.* 7, 43261–43269. <https://doi.org/10.1038/srep43261>.
15. Wilhelm, J., Birkenstock, A., Buchholz, V., Müller, A., Aly, S.A., Gruner-Labitze, K., Koehler, H., Lichtinghagen, R., Jahn, K., Groh, A., et al. (2021). Promoter Methylation of LEP and LEPR before and after Bariatric Surgery: A Cross-Sectional Study. *Obes. Facts* 14, 1–7. <https://doi.org/10.1159/000511918>.
16. Kuroda, M., Tominaga, A., Nakagawa, K., Nishiguchi, M., Sebe, M., Miyatake, Y., Kitamura, T., Tsutsumi, R., Harada, N., Nakaya, Y., and Sakaue, H. (2016). DNA Methylation Suppresses Leptin Gene in 3T3-L1 Adipocytes. *PLoS One* 11, e0160532. <https://doi.org/10.1371/JOURNAL.PONE.0160532>.
17. Hjort, L., Jørgensen, S.W., Gillberg, L., Hall, E., Brøns, C., Frystyk, J., Vaag, A.A., and Ling, C. (2017). 36 h fasting of young men influences adipose tissue DNA methylation of LEP and ADIPOQ in a birth weight-dependent manner. *Clin. Epigenet.* 9, 40. <https://doi.org/10.1186/s13148-017-0340-8>.
18. Lecoutre, S., Oger, F., Pourpe, C., Butruille, L., Marousez, L., Dickes-Coopman, A., Laborie, C., Guinez, C., Lesage, J., Vieau, D., et al. (2017). Maternal obesity programs increased leptin gene expression in rat male offspring via epigenetic modifications in a depot-specific manner. *Mol. Metabol.* 6, 922–930. <https://doi.org/10.1016/j.molmet.2017.05.010>.
19. Müller, L., Oelkrug, R., Mittag, J., Hoffmann, A., Ghosh, A., Noé, F., Wolfurum, C., Guivi Jurado, E., Klötting, N., Dietrich, A., et al. (2025). Sex-specific role of epigenetic modification of a leptin upstream enhancer in adipose tissue. *Clin. Epigenet.* 17, 1–15. <https://doi.org/10.1186/S13148-025-01830-2>.
20. Dallner, O.S., Marinis, J.M., Lu, Y.H., Birsoy, K., Werner, E., Fayzikhodjaeva, G., Dill, B.D., Molina, H., Moscati, A., Kutalik, Z., et al. (2019). Dysregulation of a long noncoding RNA reduces leptin leading to a leptin-responsive form of obesity. *Nat. Med.* 25, 507–516. <https://doi.org/10.1038/s41591-019-0370-1>.
21. Lo, K.A., Huang, S., Walet, A.C.E., Zhang, Z.C., Leow, M.K.S., Liu, M., and Sun, L. (2018). Adipocyte long-Noncoding RNA transcriptome analysis of obese mice identified lnc-Leptin, which regulates leptin. *Diabetes* 67, 1045–1056. <https://doi.org/10.2337/db17-0526>.
22. Manco, M., Crudele, A., Mosca, A., Caccamo, R., Braghini, M.R., De Vito, R., Alterio, A., Pizzolante, F., De Peppo, F., and Alisi, A. (2022). lncOb rs10487505 variant is associated with leptin levels in pediatric non-alcoholic fatty liver disease. *Pediatr. Res.* 92, 1737–1743. <https://doi.org/10.1038/s41390-022-02032-9>.
23. Geißler, C., Krause, C., Neumann, A.M., Britsemmer, J.H., Taege, N., Grohs, M., Kaehler, M., Cascorbi, I., Lewis, A.G., Seeley, R.J., et al. (2022). Dietary induction of obesity and insulin resistance is associated with changes in Fgf21 DNA methylation in liver of mice. *J. Nutr. Biochem.* 100, 108907. <https://doi.org/10.1016/J.JNUTBIO.2021.108907>.
24. Krause, C., Britsemmer, J.H., Bernecker, M., Molenaar, A., Taege, N., Geißler, C., Geißler, C., Kaehler, M., Iben, K., Judycka, A., et al. (2024). Liver microRNA transcriptome reveals miR-182 as link between type 2

- diabetes and fatty liver disease in obesity. *eLife* 12. <https://doi.org/10.7554/ELIFE.92075>.
25. Zhang, Y., Dallner, O.S., Nakadai, T., Fayzikhodjaeva, G., Lu, Y.-H., Lazar, M.A., Roeder, R.G., and Friedman, J.M. (2018). A non-canonical-PPAR γ /RXR α -binding sequence regulates leptin expression in response to changes in adipose tissue mass. *Proc. Natl. Acad. Sci. USA*, 325480. <https://doi.org/10.1101/325480>.
 26. Lu, Y.H., Dallner, O.S., Birsoy, K., Fayzikhodjaeva, G., and Friedman, J.M. (2015). Nuclear Factor- κ B is an adipogenic factor that regulates leptin gene expression. *Mol. Metabol.* 4, 392–405. <https://doi.org/10.1016/j.molmet.2015.02.002>.
 27. Fuke, T., Yoshizaki, T., Kondo, M., Morino, K., Obata, T., Ugi, S., Nishio, Y., Maeda, S., Kashiwagi, A., and Maegawa, H. (2010). Transcription factor AP-2B inhibits expression and secretion of leptin, an insulin-sensitizing hormone, in 3T3-L1 adipocytes. *Int. J. Obes.* 34, 670–678. <https://doi.org/10.1038/ijo.2009.295>.
 28. Hagberg, C.E., Li, Q., Kutschke, M., Bhowmick, D., Kiss, E., Shabalina, I.G., Harms, M.J., Shilkova, O., Kozina, V., Nedergaard, J., et al. (2018). Flow Cytometry of Mouse and Human Adipocytes for the Analysis of Browning and Cellular Heterogeneity. *Cell Rep.* 24, 2746–2756.e5. <https://doi.org/10.1016/j.celrep.2018.08.006>.
 29. Zhang, Y., Guo, K.Y., Diaz, P.A., Heo, M., and Leibel, R.L. (2002). Determinants of leptin gene expression in fat depots of lean mice. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 282, R226–R234. <https://doi.org/10.1152/AJPREGU.00392.2001>.
 30. Collares, R.V.A., Salgado, W., Da Cunha Tirapelli, D.P., and Dos Santos, J.S. (2014). The Expression of LEP, LEPR, IGF1 and IL10 in Obesity and the Relationship with microRNAs. *PLoS One* 9. <https://doi.org/10.1371/JOURNAL.PONE.0093512>.
 31. Zhu, H., Wang, G., and Qian, J. (2016). Transcription factors as readers and effectors of DNA methylation. *Nat. Rev. Genet.* 17, 551–565. <https://doi.org/10.1038/nrg.2016.83>.
 32. Yin, Y., Morgunova, E., Jolma, A., Kaasinen, E., Sahu, B., Khund-Sayeed, S., Das, P.K., Kivioja, T., Dave, K., Zhong, F., et al. (2017). Impact of cytosine methylation on DNA binding specificities of human transcription factors. *Science* 356, eaaj2239. <https://doi.org/10.1126/SCIENCE.AAJ2239>.
 33. Lee, M.J., and Fried, S.K. (2009). Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion. *Am. J. Physiol. Endocrinol. Metab.* 296, E1230–E1238. <https://doi.org/10.1152/AJPENDO.90927.2008>.
 34. Enriori, P.J., Evans, A.E., Sinnayah, P., Jobst, E.E., Tonelli-Lemos, L., Billes, S.K., Glavas, M.M., Grayson, B.E., Perello, M., Nillni, E.A., et al. (2007). Diet-Induced Obesity Causes Severe but Reversible Leptin Resistance in Arcuate Melanocortin Neurons. *Cell Metab.* 5, 181–194. <https://doi.org/10.1016/j.cmet.2007.02.004>.
 35. Van Heek, M., Compton, D.S., France, C.F., Tedesco, R.P., Fawzi, A.B., Graziano, M.P., Sybertz, E.J., Strader, C.D., and Davis, H.R. (1997). Diet-induced obese mice develop peripheral, but not central, resistance to leptin. *J. Clin. Investig.* 99, 385–390. <https://doi.org/10.1172/JCI119171>.
 36. Hinte, L.C., Castellano-Castillo, D., Ghosh, A., Melrose, K., Gasser, E., Noé, F., Massier, L., Dong, H., Sun, W., Hoffmann, A., et al. (2024). Adipose tissue retains an epigenetic memory of obesity after weight loss. *Nature*, 457–457465. <https://doi.org/10.1038/s41586-024-08165-7>.
 37. Multhaup, M.L., Seldin, M.M., Jaffe, A.E., Lei, X., Kirchner, H., Mondal, P., Li, Y., Rodriguez, V., Drong, A., Hussain, M., et al. (2015). Mouse-human experimental epigenetic analysis unmasks dietary targets and genetic liability for diabetic phenotypes. *Cell Metab.* 21, 138–149. <https://doi.org/10.1016/j.cmet.2014.12.014>.
 38. Rytka, J.M., Wueest, S., Schoenle, E.J., and Konrad, D. (2011). The Portal Theory Supported by Venous Drainage–Selective Fat Transplantation. *Diabetes* 60, 56–63. <https://doi.org/10.2337/DB10-0697>.
 39. Suárez-Cuenca, J.A., De La Peña-Sosa, G., De La Vega-Moreno, K., Banderas-Lares, D.Z., Salamanca-García, M., Martínez-Hernández, J.E., Vera-Gómez, E., Hernández-Patricio, A., Zamora-Alemán, C.R., Domínguez-Pérez, G.A., et al. (2021). Enlarged adipocytes from subcutaneous vs. visceral adipose tissue differentially contribute to metabolic dysfunction and atherogenic risk of patients with obesity. *Sci. Rep.* 11, 1831. <https://doi.org/10.1038/S41598-021-81289-2>.
 40. Fryklund, C., Neuhaus, M., Morén, B., Borreguero-Muñoz, A., Lundmark, R., and Stenkula, K.G. (2022). Expansion of the Inguinal Adipose Tissue Depot Correlates With Systemic Insulin Resistance in C57BL/6J Mice. *Front. Cell Dev. Biol.* 10, 942374. <https://doi.org/10.3389/fcell.2022.942374>.
 41. Parlee, S.D., Lentz, S.I., Mori, H., and MacDougald, O.A. (2014). Quantifying Size and Number of Adipocytes in Adipose Tissue. *Methods Enzymol.* 537, 93–122. <https://doi.org/10.1016/B978-0-12-411619-1.00006-9>.
 42. Emont, M.P., Jacobs, C., Essene, A.L., Pant, D., Tenen, D., Colleluori, G., Di Vincenzo, A., Jørgensen, A.M., Dashti, H., Stefek, A., et al. (2022). A single-cell atlas of human and mouse white adipose tissue. *Nature* 603, 926–933. <https://doi.org/10.1038/s41586-022-04518-2>.
 43. Hansen, N.S., Strasko, K.S., Hjort, L., Kelstrup, L., Houshmand-Øregaard, A., Schrölkamp, M., Schrölkamp, S., Scheele, C., Pedersen, B.K., Ling, C., et al. (2017). Fetal Hyperglycemia Changes Human Preadipocyte Function in Adult Life. *J. Clin. Endocrinol. Metab.* 102, 1141–1150. <https://doi.org/10.1210/je.2016-3907>.
 44. Klug, M., and Rehli, M. (2006). Functional Analysis of Promoter CpG-Methylation using a CpG-Free Luciferase Reporter Vector. *Epigenetics* 1, 127–130. <https://doi.org/10.4161/EPI.1.3.3327>.
 45. Harrison, L., Schriever, S.C., Feuchtinger, A., Kyriakou, E., Baumann, P., Pfuhlmann, K., Messias, A.C., Walch, A., Tschöp, M.H., and Pfluger, P.T. (2019). Fluorescent blood–brain barrier tracing shows intact leptin transport in obese mice. *Int. J. Obes.* 43, 1305–1318. <https://doi.org/10.1038/S41366-018-0221-Z>.
 46. Krause, C., Geißler, C., Tackenberg, H., El Gammal, A.T., Wolter, S., Spranger, J., Mann, O., Lehnert, H., and Kirchner, H. (2020). Multi-layered epigenetic regulation of IRS2 expression in the liver of obese individuals with type 2 diabetes. *Diabetologia* 63, 2182–2193. <https://doi.org/10.1007/s00125-020-05212-6>.
 47. Sievert, H., Krause, C., Geißler, C., Grohs, M., El-Gammal, A.T., Wolter, S., Mann, O., Lehnert, H., and Kirchner, H. (2021). Epigenetic Downregulation of FASN in Visceral Adipose Tissue of Insulin Resistant Subjects. *Exp. Clin. Endocrinol. Diabetes* 129, 674–682. <https://doi.org/10.1055/a-1150-7446>.
 48. Pfaffl, M.W. (2001). A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res.* 29, e45. <https://doi.org/10.1093/NAR/29.9.E45>.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
anti-Leptin antibody	R&D systems, US	AF498; RRID:AB_355394
anti-Leptin antibody, polyclonal rabbit anti-leptin antibody	Abcam, US	ab16227; RRID:AB_302331
Polyclonal Rabbit Anti-Goat Immunoglobulins/HRP	Agilent Technologies (Dako), US	P0449; RRID:AB_2617143
goat anti-rabbit Alexa 750 antibody	Invitrogen, US	A21039; RRID:AB_2535710
Biological samples		
Visceral adipose tissue, human		N/A
Chemicals, peptides, and recombinant proteins		
3-Isobutyl – 1-methylxanthin	Sigma Aldrich, US	I7018
Bovine serum albumin	Sigma Aldrich, US	A9418
CLARITY MAX Western ECL Substrate	Bio-Rad Laboratories GmbH, US	#1705062
dexamethasone	Sigma Aldrich, US	D4902
DMEM with high glucose	GIBCO, Life Technologies	#31966021
Fetal Bovine Serum One Shot	GIBCO, Life Technologies	N/A
HCS LipidTOX Green neutral lipid stain)	Invitrogen, US	H34475
HindIII-HF	New England Biolabs, US	NEB #R3104
insulin: Humalog 100 IE/mL	Eli Lilly and Company, Indianapolis, US	N/A
Mini_PROTEAN TGX Stain-Free gradient gels	Bio-Rad Laboratories GmbH, US	#10018639
M.SssI	New England Biolabs, US	NEB #0226
NcoI-HF	New England Biolabs, US	NEB #R0193
Penicillin-Streptomycin	GIBCO, Life Technologies	15070063
Pierce MS-compatible Magnetic IP Kit	ThermoFisherScientific, US	90408
polyvinylidene fluoride membrane	Merck Millipore, Ireland	IPVH00010
Quick ligase	New England Biolabs, US	NEB #M2200
Critical commercial assays		
DUAL-GLO Luciferase Assay	Promega, US	E2920
EpiTect Fast DNA Bisulfite Kit	QIAGEN; Netherlands	59802
Formalin 10% neutral buffered	Sigma-Aldrich, Germany	HT501128
Histocore Spectra H&E Stain System S1	Leica, Germany	3801654
High-Capacity cDNA Reverse Transcription Kit	ThermoFisherScientific, US	4374966
lipofectamine2000	ThermoFisherScientific, US	11668019
miRNeasy Mini Kit	QIAGEN; Netherlands	217004
mouse/rat leptin Quantikine ELISA Kit	R&D Systems, US	MOB00B
PrimeTime Gene Expression Master Mix	Integrated DNA Technologies, US	1055771
PyroMark PCR Kit	QIAGEN; Netherlands	978703
PyroMark Q48 Advanced CpG Reagents	QIAGEN; Netherlands	974022
QIAmp Fast DNA tissue kit	QIAGEN; Netherlands	51404
QIAmp Mini kit	QIAGEN; Netherlands	51304
Quick-DNA Microprep Plus Kit	Zymo Research GmbH, Germany	D4074
RevertAid cDNA synthesis kit	ThermoFisherScientific, US	K1622
GoTAQ qPCR System	Promega, US	A6001
Experimental models: Cell lines		
3T3-L1	American Type Culture Collection (ATCC), US	N/A

(Continued on next page)

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
HEK293T		N/A
Experimental models: Organisms/strains		
Lepob (ob/ob)	Jackson Laboratories	RRID: MGI:5816460
WT C57BL/6J male	Janvier Labs, Saint-Berthevin, Cedex, France	N/A
WT C57BL/6NCRl male	Charles River	N/A
Oligonucleotides		
PrimeTime assay <i>Acaca/Acc1</i>	Integrated DNA Technologies, US	Mm.PT.58.12492865
PrimeTime assay <i>Fasn</i>	Integrated DNA Technologies, US	Mm.PT.58.14276063
PrimeTime assay <i>Glut4/Slc2a4</i>	Integrated DNA Technologies, US	Mm.PT.58.9683859
PrimeTime assay <i>Hprt</i>	Integrated DNA Technologies, US	Mm.PT.39a.22214828
PrimeTime assay <i>Lep</i>	Integrated DNA Technologies, US	Mm.PT.58.13515402
PrimeTime assay <i>LEP</i>	Integrated DNA Technologies, US	Hs00174877_m1
PrimeTime assay <i>Lipe</i>	Integrated DNA Technologies, US	Mm.PT.58.30708147
PrimeTime assay <i>IncOb</i> – custom	Integrated DNA Technologies, US	5'CTAGGCCACATTCCTGATAC; 5'GACTTTGCCTTCTGGTTCTTG; 5'-/56-FAM/AGGACCAAG/ZEN/ ACCACCAAGCCAATC/3IABkFQ
PrimeTime assay <i>Mlxip/ChREBP</i>	Integrated DNA Technologies, US	Mm.PT.56a.33592172
PrimeTime assay <i>Pnpla2</i>	Integrated DNA Technologies, US	Mm.PT.56a.13424398.g
PrimeTime assay <i>RPL37A</i>	Integrated DNA Technologies, US	Hs01102345_m1
PrimeTime assay <i>Srebf1</i>	Integrated DNA Technologies, US	Mm.PT-58.8508227
<i>Hprt</i> - SYBR	Integrated DNA Technologies, US	fwd-GCAGTACAGCCCCAAAATGG rev-AACAAAGTCTGGCCTGTATCCAA
<i>InsR</i> -SYBR	Integrated DNA Technologies, US	fwd-ATGGGCTTCGGGAGAGGAT rev-GGATGTCCATACCAGGGCAC
<i>Ppara</i> - SYBR	Integrated DNA Technologies, US	fwd-AGAGCCCCATCTGTCTCTC rev-ACTGGTAGTCTGCAAAACCAA
ms-RS1-fwd	Integrated DNA Technologies, US	GGGTAGTTGAAATAATTAGTTAGT
ms-RS1-rev	Integrated DNA Technologies, US	/bio-CCTCAAACACTCCAAACATACA
ms-RS1-sequencing primer	Integrated DNA Technologies, US	AATTGGTGGTTTTGGTATTA
hu-RS1-fwd	Integrated DNA Technologies, US	GTAGTAGGGGTATTATTATAGGATTATTTGA
hu-RS1-rev	Integrated DNA Technologies, US	ACAAAATATCTTCCAATCAATTCTTTAAC
hu-RS1-sequencing primer	Integrated DNA Technologies, US	TTGAAGAAGTATTGGTTAAGAAG
RS1 – luci-fwd	Integrated DNA Technologies, US	AGCTTTCTGGCATCATCGTGACCACGG TTTTTCCCACAGCGGTGCCTAACAC
RS1-luci-rev	Integrated DNA Technologies, US	CATGGTGTAGGACACCGCTGTGGGAAA ACCGCTGGTCACGATGATGCCAGAA
RS1-fwd-bio – massspec	Integrated DNA Technologies, US	/bio-TTCTGGCATCATCGTGACCAGC GGTTTTTCCCACAGCGGTGCCTAACAC
RS1-rev-massspec	Integrated DNA Technologies, US	CATGGTGTAGGACACCGCTGTGG GAAAACCGCTGGTCACGATGATGCCAGAA
pRL-SV40 (Renilla SC40 plasmid)	Promega, US	E2231
Recombinant DNA		
CpG-free plasmid pCpGL-CMV	⁴⁴	N/A
Luci-RS1-CpGfree	created by the authors	N/A
Software and algorithms		
DIA-NN software	GitHub repository	version 1.8.1
FlowPILOT III software	Union Biometrica Inc., US	N/A
GraphPad PRISM	GraphPad Software, Inc., US	version 10.5.0

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Image Lab	Bio-Rad Laboratories GmbH, US	version 6.01.34
limma-package	Bioconductor	version 3.56.2
Microsoft Excel	Microsoft	Office 15 & 16
PyroMark Assay Design 2.0 software (QIAGEN, Germany)	QIAGEN; Netherlands	version 2.0.2.5
PyroMark Q48 Autoprep software	QIAGEN; Netherlands	version 2.4.2
R Studio	Posit PBC	2023.09.1+494
ThermoFisher Scientific Cloud	ThermoFisher, US	N/A
Other		
chow Diet 1314	Altromin, Germany	1314
58% HFD	Research Diets, US	D12331
60% HFD	Ssniff, Germany	E15742
60% High fat diet (HFD)	Research Diets, US	D12492

EXPERIMENTAL MODELS AND STUDY PARTICIPANT DETAILS

Mice models were performed at two institutions: In the animal facility of the Center of Brain, Behaviour and Metabolism, University of Lübeck, Germany and at the Helmholtz Diabetes Center, Munich, Germany. The tissues were collected from different studies, using high fat diets with similar fat content but different fat compositions, adding another layer of robustness to the observed direction of the results.

Diet-induced obesity model

Study approval

Animal procedures were approved by the ethical committee of the Ministry of Energy Change, Rural Areas & Consumer Protection (MELUR) Schleswig-Holstein, Germany (V 242-59721/2016).

Mice

The longitudinal diet-induced obesity (DIO) mouse model, including the i.p. glucose tolerance test and plasma insulin data were published previously.²³ In brief, male C57BL/6NCr1 mice were housed under constant temperature (22 ± 1°C) and 12-hour light/dark cycle with *ad libitum* access to food and water. At 5 weeks of age, mice were randomized into two groups of similar body weight. The control group was fed a chow diet. The treated group was fed a 60 % high-fat diet (HFD, D12492, Research Diets, US). Subcohorts were sacrificed at weeks 1, 2, 4, 5, 6, 7, 8 or 12, tissues collected and immediately snap-frozen and stored at -80°C. The amount of animals per group differed between the weeks, due to identified outliers and due to two mouse cohorts which were combined: One mouse cohort included the timepoints weeks 1, 2, 4, 8, 12 and the other weeks 4, 5, 6, 7, 8.

Leptin measurement

To measure circulating leptin levels, we used plasma of weight- and age-matched mice (chow = 5; HFD = 6 – 7 animals) which were housed and treated as described above in the same facility. Blood was withdrawn from a subgroup of mice by incising the tail vein and collected in EDTA coated tubes. Leptin was measured using the mouse/rat leptin Quantikine ELISA Kit after manufacturer's protocol. Plasma from chow mice was diluted 1:20 and from HFD mice 1:40 or 1:80.

Adipocyte size sorting

Study approval

Animal procedures were approved by the State of Bavaria, Germany (55.2.1.54-2532-99-16) and in accordance with German Law for Animal Protection, FELASA's guidelines for animal research, EU Directive 2010/63/EU.

Mice

The adipocyte size sorting mouse study was performed in adult male C57BL/6J mice, housed on 12 h light/dark cycle with *ad-libitum* access to food and water. From 5 weeks of age, mice were fed a 60% high fat diet (E15742, Ssniff, Germany corresponding to D12492 Research Diets, US) or continued on chow diet for 10 – 11 weeks.

Adipocyte methylation and adipocyte size sorting

Adipocytes were isolated from eWAT directly after cervical dislocation and used for adipocyte methylation analysis or size sorting. The adipose tissue was minced using razor blades, directly transferred to digestion medium (1x DMEM, 1mg/mL collagenase, 1% BSA) and incubated for 30 min, 37°C, 1000 rpm. Larger particles were removed using a 250 µm mesh. Floating adipocytes were collected after centrifugation for 5 min at 500 x g. After staining adipocytes with HCS LipidTOX Green neutral lipid stain (1:1000) for 30 min at room temperature, adipocytes were sorted using the COPAS FP500 with the FlowPILOT III software (Union Biometrica

Inc., US). Sorting gates and criteria were determined beforehand by using stained and unstained adipocytes from epididymal adipose tissue of chow or HFD-fed mice respectively. Adipocytes were identified by emission, size and optical density using a 488 nm solid state laser. Sorting criteria for size were defined by time-of-flight (TOF) against extinction into 'small' and 'large' for adipocytes from chow-fed mice and 'small', 'intermediate' and 'large' for adipocytes from HFD-fed mice (File S1, Tables S1 and S2). The data of the intermediate and large fractions were analyzed together. The different size fractions of adipocytes were sorted dropwise at circa 10,000 – 40,000 cells per fraction under a stable flow rate into 50 mL falcons. DNA was extracted by adding 1:100 Triton-X to the cell suspension and mixing vigorously for 30 s. The suspension was rotated for 30 min at 4°C, followed by another 30s mix. 1 μ L/10 mL Glycol Blue was added and centrifuged for 15 min at 4°C. The supernatant was discarded, and the pellet resuspended. For further isolation, the Quick-DNA Microprep Plus Kit (Zymo Research GmbH, Germany) was used after manufacturer's protocol. DNA was used for methylation analysis as described in the subsection.

Dietary interventions and genetic alteration

Study approval

Animal procedures were approved by the State of Bavaria, Germany (55.2.1.54-2532-99-16) and in accordance with German Law for Animal Protection, FELASA's guidelines for animal research, EU Directive 2010/63/EU.

Mice

Ob/ob mice were housed on 12 h light/dark cycle with ad-libitum access to food (chow diet) before sacrifice and eWAT collection at age of 12 weeks.

The weight cycling study was already published²⁴ and performed in male C57BL/6J mice, housed on 12 h light/dark cycle with ad-libitum access to food and water. Before intervention, mice were subjected to 58% HFD (Research Diets, D12331) for 24 weeks. The HFD group continued on HFD throughout the study period, while two other groups underwent interventions: The diet switch group (HC) switched to chow after 12 weeks of HFD. The weight cycling group (Yoyo) was switched to chow for the first 12 weeks of the study and then switched back to HFD for the other 12 weeks of the study. Age-matched chow-fed mice served as controls. Mice were fasted for 3 hours before organ collection.

For acute overnight fasting study, we used an already published regime⁴⁵: male C57BL/6J mice, housed as described above, were subjected to 60% HFD (E15742, Sniff) for 27 weeks. Age-matched chow-fed mice served as controls. For each group, a subgroup underwent an overnight fast of 16 hours before the sacrifice at 9 am.

Human visceral adipose tissue samples

Approval of the study was granted by the local ethics committee (Ethik Kommission der Ärztekammer Hamburg, PV4889, 2015). Visceral adipose tissue biopsies from humans with obesity were collected during bariatric surgery from overnight fasted subjects as previously described.⁴⁶ All participants provided informed consent. Information about the cohort is given in Table 1.

METHOD DETAILS

Exclusion criteria for data or subjects

Malperforming samples due to technical difficulties were identified after quality checks in pyrosequencing (low peak height) or in qPCR (high deviation in the replicates, abnormalities in the melt curve) and omitted, if no replication was possible, from the analysis as individual values. Complete subject outliers were identified by outlier testing after "Robust regression followed by Outlier removal" (ROUT) in GraphPad PRISM and omitted from analysis if they were outliers in most or all of the measured parameters.

Adipocyte size measurement in fixed adipose tissue

Epididymal adipose tissue was dissected from mice that had been subjected to prolonged feeding of 58% HFD for 43 weeks and of age-matched chow controls.⁴⁵ For morphometric evaluation of eWAT, adipose tissue specimens were fixed in 4 % (w/v) neutrally buffered formalin, embedded in paraffin and cut into 3 μ m slices for H&E staining. Stained tissue sections were scanned with an AxioScan. Z1 digital slide scanner (Zeiss, Jena, Germany) equipped with a 20X magnification objective. Images were evaluated using the commercially available image analysis software Definiens Developer XD 2 (Definiens AG, Munich, Germany). The calculated parameter was the mean adipocyte section profile area in μ m². Images were used for correlation analysis.

Immunofluorescent analysis of leptin content

Immunofluorescence detection of leptin was performed on epididymal adipose tissue sections from mice that were either fed chow or 60% HFD for 42 weeks that were fixed and sectioned as described above using specific antibodies (1:500, #ab16227, and secondary antibody: 1:100, A21039).

The stained tissue sections were scanned with an AxioScan 7 digital whole slide scanner (Zeiss, Oberkochen, Germany) equipped with a 20x magnification objective. AI-based digital image analysis (Visiopharm, Hoersholm, Denmark) was used for morphometric determination of the mean adipocyte section profile areas, as well as the percentage of leptin-positive stained area per total adipose tissue section area.

Gene expression analysis

RNA from human samples was extracted and cDNA synthesized as previously described.⁴⁷ RNA from mouse samples and cells was extracted using the miRNeasy Mini Kit after manufacturer's protocol of RNA purification from 60 – 100 mg mouse adipose tissue including tissue disruption with FISHERBRAND Bead Mill 24 (Fisher Scientific GmbH, Germany) and the suggested DNase digestion. Complementary DNA (cDNA) of mouse and cells was synthesized using the RevertAid cDNA synthesis kit, High-Capacity cDNA Reverse Transcription Kit. For quantitative polymerase chain reaction (qPCR) cDNA was diluted to 2.5 ng/ μ L for a final input of 10 ng cDNA per reaction. The PrimeTime Gene Expression Master Mix was used with assays given in the [key resources table](#) and single- or multiplexed in a final reaction volume of 10 μ L. For *InsR* and *Ppara*, gene expression was measured using the GoTAQ qPCR system after manufacturer's protocol in a final reaction volume of 20 μ L. Measurements were performed in duplicates. qPCR was performed on QuantStudio 5 Real-time PCR-System (ThermoFisherScientific, US). The runs were analyzed and thresholds between runs adjusted using the ThermoFisher Scientific Cloud tool. Fold change was calculated after Pfaffl⁴⁸ using the duplicate's mean CT values. Hypoxanthine-phosphoribosyl transferase gene (*Hprt*, mouse) or Ribosomal protein 37a (*RPL37a*, human) served as housekeeper.

Methylation analysis

For pyrosequencing analysis, DNA of 60 – 100 mg whole adipose tissue was isolated using the QIAmp Fast DNA tissue kit or QIAmp Mini Kit and DNA measured using the Qubit spectrophotometer (ThermoFisher Scientific, US). DNA was bisulfite converted using the EpiTect Fast DNA Bisulfite Kit after manufacturer's instructions. The pyrosequencing assays for mouse and human *Lep* regulatory enhancer site RS1 were designed using the PyroMark Assay Design 2.0 software. Polymerase chain reaction was performed after thorough implementation of the assays using the PyroMark PCR Kit with 1 μ L bisulfite converted DNA as input (cycles: 10 min, 95°C; (30 s, 94°C; 25 s, 49.5°C(ms)/52.9°C(hu); 25 s, 72°C)x40(ms)/45(hu); 10 min, 72°C; assays see [key resources table](#); and genomic position in [File S1](#), [Table S3](#)). PCR product was confirmed on a 1% agarose gel in 1x TAE-buffer. The pyrosequencing runs were programmed using the PyroMark Q48 Autoprep software and performed on the PyroMark Q48 Autoprep (QIAGEN, Netherlands) after the machine's and manufacturer's instructions with the sequencing primer of the assay. All presented mouse methylation data is normalized to a standard curve of the RS1 assay to allow better comparability between the different mouse cohorts.

Luciferase assay

The insert for RS1 was ordered as single-strand oligonucleotides (see [key resources table](#)) and duplexed. The insert was cloned upstream of the CMV promoter and luciferase of the CpG-free plasmid pCpGL-CMV, a gift from Prof. Rehli⁴⁴ using restriction enzymes NcoI-HF and HindIII-HF and Quick ligase. Methylation of the vectors was performed using M.SssI, a mock-methylation reaction without the addition of M.SssI served as control. Vectors were gel purified. Transfection into HEK293T was performed using lipofectamine2000 in 96-well plates as triplicates per site with biological replicates. Transfection efficiency was controlled with a co-transfection of Renilla-SC40 plasmid at a ratio of 1:1. Renilla and Firefly luciferase signals were measured using the DUAL-GLO Luciferase Assay 24h after transfection. Transfections were performed as technical triplicates and biological replicates, as indicated in the figure. Each signal was normalized by its Renilla signal before each normalized signal was divided by a normalized mock-methylation signal of the biological replicate. The average of these adjusted signals was taken as the value for the respective biological replicate.

Mass-spectrometry analysis

For mass-spectrometry analysis of the proteins binding to RS1 the PIERCE MS-compatible Magnetic IP Kit was used. Methylated (as described in the luciferase assay) and unmethylated oligonucleotides were used. Briefly, 5 μ g biotinylated double-stranded oligonucleotides containing the RS1 CpG sites (methylated or unmethylated) were incubated with either 200 μ g protein extract from epididymal adipose tissue of mice on HFD for 12 weeks ($n = 3$ for each methylated vs unmethylated) or 100 μ g nuclear protein extract of differentiated 3T3-L1 cells (13 days differentiated, as described below; $n = 3$ for unmethylated strand, $n = 2$ for methylated strand) in a final volume of 500 μ L in IP-MS Cell lysis buffer overnight at 4°C. The immunoprecipitation was conducted as per manufacturer's instructions separately for each biological replicate. For the liquid chromatography coupled mass spectrometry, DNA-protein complexes were lyophilized and dissolved in 0.1% formic acid in water for mass spectrometric analysis. The reconstituted complexes were loaded onto C18 EvoTip disposable trap columns and chromatographically separated using an EvoSep One system (EvoSep, Odense, Denmark) with a C18 Performance column (EV1137, 15cm x 150 μ m, 1.5 μ m) and an extended 15 SPD method (88 min gradient, 220 nl/min). A nano-electrospray ion source linked the system to the hybrid TIMS quadrupole TOF mass spectrometer (Bruker timsTOF Flex HT), which ran in the diaPASEF mode with specific settings for scan range, ion mobility, and mass accuracy ([File S1](#), [Table S4](#)). Data processing was performed using DIA-NN software with specific parameters shown in ([File S1](#), [Table S5](#)). The analysis of the generated protein group list was performed using R Studio. First, the data were filtered for transcription factors obtained from the mouse RIKEN transcription factor database (accessed 12/12/2023). Methylated and unmethylated data were analyzed for the differential abundance of proteins between methylated and unmethylated strand using the limma-package with linear model fit and correction using the empirical Bayes-method. Data from 3T3-L1 and mouse adipose tissue were analyzed separately.

Protein isolation for mass spectrometry

Protein isolation from epididymal adipose tissue from week 12 DIO mice was performed using the Bio-Plex Cell lysis kit after manufacturer's protocol with a repeated centrifugation step to purify the protein sample from the lipid layer. Homogenization of 300 μ L cell lysis buffer with ca. 50 mg eWAT was performed with a bead mill.

Nuclear proteins from 13-day differentiated 3T3 cells were extracted using the Ne-Per Nuclear and Cytoplasmic Extraction Kit. Cells were washed three times with cold 1xDPBS and harvested using a cell scraper. Cells were centrifuged at 6000xg for 5 min and the supernatant discarded. Further steps were performed after manufacturer's instructions, with following changes: The pellet was resuspended in 300 μ L CER I; 165 μ L CERII and 150 μ L NER were further used.

Proteins were quantified using the PIERCE BCA Protein Assay Kit after manufacturer's protocol. Absorbance was measured using the plate reader CLARIOstar Plus at 562 nm.

3T3-L1 cell culture differentiation

For differentiation into adipocytes, 3T3-L1 ATCC cells were seeded at 2×10^4 cells/well in a 12-well plate with proliferation medium (1xDMEM high glucose; 10% FBS, 1% Penicillin-Streptomycin). One day after confluency, cells were stimulated with induction medium (1xDMEM high glucose, 0.25 μ M dexamethasone, 0.5 mM 3-isobutylmethylxanthine, 1 μ g/mL insulin) for 72 h before being switched to differentiation medium (proliferation medium with the addition of 1 μ g/mL insulin). Differentiation medium was changed every other day.

Immunoblotting

Adipose tissue (iWAT and eWAT, 40 – 80 mg) was homogenized in lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH7.4, 0.5% wt/vol sodium deoxycholate, 1% vol/vol Nonidet P40, 1 mM EDTA, 1mMNaVO₄, 10mMNaF, cOmplete Protease Inhibitor Cocktail (Roche), with freshly added 1mM PMSF) to isolate total protein. Protein concentration was determined with BCA-assay. For immunoblotting, 15 μ g total protein mixed 1:4 with loading dye (heated to 98°C for 5 min) was separated on Mini PROTEAN TGX Stain-Free gradient gels and transferred onto a polyvinylidene fluoride. Membranes were blocked with 5% milk powder in TBS-T and incubated overnight at 4°C with anti-Leptin antibody (1:1000, AF498). After 1 h of washing in TBS-T, membranes were incubated with secondary antibody (1:5000, P0449) for 1 h, washed again for 1 h and visualized using CLARITY MAX Western ECL Substrate and ChemiDoc, Touch Imaging System (Bio-Rad Laboratories GmbH, US). Band intensity was quantified with the Image Lab software and data were normalized to total protein lane (stain free) and then to a calibrator on each blot to allow comparison between plots.

QUANTIFICATION AND STATISTICAL ANALYSIS

Data were analyzed as indicated in the figure legends using GraphPad PRISM 10.5.0 (GraphPad Software, Inc, US) and are presented as mean \pm SD. For one-way, two-way and two-way repeated measure ANOVA as well as two-tailed t-test, normality (Shapiro-Wilk, D'Agostino-Pearson omnibus) was verified beforehand. When normality was not given for one-way ANOVA, data was analyzed using the Kruskal-Wallis test- For two-way (repeated measure) ANOVA or t-test, data was log-transformed and two-way ANOVA or t-test repeated. The precise alternative tests are given in the figure legends. Also, the n-value can be extracted from the graphs. Significance was assumed for $p < 0.05$ if not stated differently. For gene expression data, the Δ CT values were taken for statistical analysis. Schematics were created using BioRender.com. Data were visualized using GraphPad PRISM 10.5.0 (GraphPad Software, Inc, US) or R Studio.